Status | Study |
Completed |
Study Name: Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL) Condition: Lymphoma, Mantle-Cell Date: 2010-10-13 Interventions: Drug: Combination of dexamethasone, ofatumumab and bendamustine |
Completed |
Study Name: Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma Condition: Lymphoma, Mantle-Cell Date: 2009-10-08 Interventions: Biological: Tositumomab and Iodine I 131 Tositumomab followed by CHOP Patients will receive an infusion |
Completed |
Study Name: Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma Condition: Lymphoma, Mantle-Cell Date: 2009-10-07 Interventions: Drug: Rituximab, Bendamustine, Cytarabine Rituximab IV 375 |
Active, not recruiting |
Study Name: A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) Condition: Mantle Cell Lymphoma Lymphoma, Mantle-Cel Date: 2009-04-01 Interventions: Drug: Lenalidomide |
Terminated |
Study Name: Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2009-02-18 Interventions: Drug: ZARNESTRA (Tipifarnib) |
Terminated |
Study Name: A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2009-02-12 Interventions: Drug: P276-00 P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 m |
Completed |
Study Name: Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL) Condition: MANTLE CELL LYMPHOMA Date: 2008-11-05 Interventions: Drug: Lenalidomide and Dexametasone Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral ad |
Completed |
Study Name: Safety and Efficacy of RAD001 in Patients With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy. Condition: Lymphoma, Mantle- Cell Date: 2008-06-19 Interventions: Drug: RAD001 |
Completed |
Study Name: Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2007-12-19 Interventions: Drug: modified Hyper-CVAD rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorub |
Completed |
Study Name: Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2007-12-19 Interventions: Drug: Bortezomib Administered |